Whitehawk Therapeutics to Showcase ADC Pipeline at Key Investor Conferences — Whitehawk Therapeutics, Inc.

Event summary

Whitehawk Therapeutics will participate in three investor conferences in September 2026.
CFO Scott Giacobello and CSO David Dornan will lead a fireside chat at Morgan Stanley's conference on September 15, 2026.
The company's ADC portfolio includes HWK-007, HWK-016, and HWK-206, licensed from WuXi Biologics.
Whitehawk's platform leverages CPT113 technology with proprietary CBCR bioconjugation process.
The company has an option agreement with Hangzhou DAC for up to five additional ADC programs.

The big picture

Whitehawk Therapeutics is positioning itself as a key player in the ADC space, competing with established players by leveraging proprietary technology. The company's participation in major investor conferences signals an effort to boost visibility and attract potential partners or investors. The oncology therapeutics market continues to evolve, with ADCs representing a growing segment due to their targeted approach in treating difficult-to-treat cancers.

What we're watching

Pipeline Progress: How Whitehawk's ADC candidates advance through clinical stages will determine its competitive positioning.
Strategic Partnerships: Whether the company can leverage its agreements with WuXi Biologics and Hangzhou DAC to accelerate development.
Market Perception: The impact of investor conference presentations on Whitehawk's valuation and access to capital.